Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Semaglutide in Obesity: Unmet Needs in Men
Mojca Jensterle, Manfredi Rizzo, Andrej Janež
Diabetes Therapy (2023) Vol. 14, Iss. 3, pp. 461-465
Open Access | Times Cited: 18

Showing 18 citing articles:

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Ania M. Jastreboff, Lee M. Kaplan, Juan P. Frías, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 6, pp. 514-526
Closed Access | Times Cited: 459
Sex- and Gender-Related Differences in Obesity: From Pathophysiological Mechanisms to Clinical Implications
Andrijana Koceva, Rok Herman, Andrej Janež, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7342-7342
Open Access | Times Cited: 16
Sex, race, and BMI in clinical trials of medications for obesity over the past three decades: a systematic review
Moath S. Alsaqaaby, Sarah Cooney, Carel W. le Roux, et al.
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 6, pp. 414-421
Closed Access | Times Cited: 13
One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice
Hamlet Gasoyan, Elizabeth R. Pfoh, Rebecca Schulte, et al.
JAMA Network Open (2024) Vol. 7, Iss. 9, pp. e2433326-e2433326
Open Access | Times Cited: 13
Role of lifestyle and glucagon‐like peptide‐1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases
Anna Giannakogeorgou, Michael Roden
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. S1
Open Access | Times Cited: 11
Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview
Özge Telci Çaklılı, Mustafa Cesur, Dimitri P. Mikhailidis, et al.
Diabetes Metabolic Syndrome and Obesity (2023) Vol. Volume 16, pp. 1767-1774
Open Access | Times Cited: 16
Safe Continuation of Glucagon-like Peptide 1 Receptor Agonists at Endoscopy: A Case Series of 57 Adults Undergoing Endoscopic Sleeve Gastroplasty
Daniel B. Maselli, Daniel J. Lee, Danse Bi, et al.
Obesity Surgery (2024) Vol. 34, Iss. 7, pp. 2369-2374
Closed Access | Times Cited: 5
Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m2 in the phase 2 trial of survodutide, a glucagon/GLP‐1 receptor dual agonist
Carel W. le Roux, Oren Steen, Kathryn Jean Lucas, et al.
Diabetes Obesity and Metabolism (2025)
Open Access
Sex Differences in the Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta‐Analysis
Yucheng Yang, Liyun He, Sang Hoon Han, et al.
Journal of Diabetes (2025) Vol. 17, Iss. 3
Open Access
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
Richard Salvador, Carla Moutinho, Carla Silva, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 399-399
Open Access
MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women
Ilaria Milani, Marianna Chinucci, Frida Leonetti, et al.
Biomedicines (2025) Vol. 13, Iss. 4, pp. 855-855
Open Access
Semaglutide for weight loss: unanswered questions
Ploutarchos Tzoulis, Stephanie Baldeweg
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 4
Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis
Peter Rossing, Stephen C. Bain, Heidrun Bosch‐Traberg, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 9
A Real-World Study of the Effectiveness and Safety of Semaglutide for Weight Loss
Ploutarchos Tzoulis, Michael Batavanis, Stephanie Baldeweg
Cureus (2024)
Open Access | Times Cited: 2
Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease
Emmanouil Korakas, Aikaterini Kountouri, George Pavlidis, et al.
Journal of the Endocrine Society (2024) Vol. 8, Iss. 8
Open Access | Times Cited: 2
Influence of BMI-associated genetic variants and metabolic risk factors on weight loss with semaglutide: a longitudinal clinico-genomic cohort study
Matthew E. Levy, Natalie Telis, Kelly M. Schiabor Barrett, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Representation of racialised and ethnically diverse populations in multicentre randomised controlled trials of GLP-1 medicines for obesity: a systematic review and meta-analysis of gaps
Yaanu Jeyakumar, Lisa Richardson, Shohinee Sarma, et al.
BMJ Global Health (2024) Vol. 9, Iss. 11, pp. e017177-e017177
Open Access | Times Cited: 1
Insights into the Neurobiology of Weight Loss after Bariatric Surgery and GLP-1R Agonists
Tyler Cook, Kelly N. Z. Fuller, Darleen A. Sandoval
Neuropharmacology (2024), pp. 110269-110269
Closed Access
Page 1

Scroll to top